Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Juvenile myoclonic epilepsy Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Juvenile myoclonic epilepsy strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Epilepsy with myoclonic-atonic seizures Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Epilepsy with myoclonic-atonic seizures strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Neonatal seizures Indication Strategy Report 2026: KCNQ2, Trials and Deals
23 July 2026
2026 Neonatal seizures strategy: epidemiology, KCNQ2 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Antisynthetase syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Antisynthetase syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Palindromic rheumatism Indication Strategy Report 2026: IL-6, Trials and Deals
23 July 2026
2026 Palindromic rheumatism strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Enteropathic arthritis Indication Strategy Report 2026: IL-23, Trials and Deals
23 July 2026
2026 Enteropathic arthritis strategy: epidemiology, IL-23 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Reactive arthritis Indication Strategy Report 2026: TNF, Trials and Deals
23 July 2026
2026 Reactive arthritis strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Calcium pyrophosphate deposition disease Indication Strategy Report 2026: NLRP3, Trials and Deals
23 July 2026
2026 Calcium pyrophosphate deposition disease strategy: epidemiology, NLRP3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Tracheobronchomalacia Indication Strategy Report 2026: MMP9, Trials and Deals
23 July 2026
2026 Tracheobronchomalacia strategy: epidemiology, MMP9 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Chylothorax Indication Strategy Report 2026: VEGFR3, Trials and Deals
23 July 2026
2026 Chylothorax strategy: epidemiology, VEGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Acute eosinophilic pneumonia Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Acute eosinophilic pneumonia strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cryptogenic organizing pneumonia Indication Strategy Report 2026: JAK1, Trials and Deals
23 July 2026
2026 Cryptogenic organizing pneumonia strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness.